Explore

Trendline Trendline
Gilead Cuts 87% of Arcellx Workforce Following Acquisition

Gilead Cuts 87% of Arcellx Workforce Following Acquisition

Gilead Cuts 87% of Arcellx Workforce Following Acquisition
Reuters Reuters
Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

By Deena Beasley LOS ANGELES, May 7 (Reuters) - Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said it now expects a loss for the year due to charges and financing costs related to recent acquisitions.
Reuters Reuters
California's highest court to consider whether drugmakers have 'duty to innovate'

California's highest court to consider whether drugmakers have 'duty to innovate'

May 6 (Reuters) - The California Supreme Court will on Wednesday consider whether manufacturers of drugs that are considered safe are legally obligated to continue developing drugs that are allegedly safer.
Trendline Trendline
Merck Completes Acquisition of Terns Pharmaceuticals, Expanding Oncology Pipeline

Merck Completes Acquisition of Terns Pharmaceuticals, Expanding Oncology Pipeline

Merck Completes Acquisition of Terns Pharmaceuticals, Expanding Oncology Pipeline
Trendline Trendline
Angelini Pharma Acquires Catalyst Pharma for $4.1 Billion, Expanding into U.S. Market

Angelini Pharma Acquires Catalyst Pharma for $4.1 Billion, Expanding into U.S. Market

Angelini Pharma Acquires Catalyst Pharma for $4.1 Billion, Expanding into U.S. Market
Trendline Trendline
Sarepta Therapeutics Reports Strong Q1 2026 Financial Results and Advances in Genetic Medicine

Sarepta Therapeutics Reports Strong Q1 2026 Financial Results and Advances in Genetic Medicine

Sarepta Therapeutics Reports Strong Q1 2026 Financial Results and Advances in Genetic Medicine
Trendline Trendline
Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement

Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement

Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement
Trendline Trendline
IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026

IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026

IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026
Trendline Trendline
North America Biotechnology Market Projected to Reach USD 2168.91 Billion by 2035

North America Biotechnology Market Projected to Reach USD 2168.91 Billion by 2035

North America Biotechnology Market Projected to Reach USD 2168.91 Billion by 2035
Trendline Trendline
Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings
Trendline Trendline
Amgen Announces $300 Million Investment in Puerto Rico Manufacturing Facility

Amgen Announces $300 Million Investment in Puerto Rico Manufacturing Facility

Amgen Announces $300 Million Investment in Puerto Rico Manufacturing Facility
Trendline Trendline
Citius Oncology Secures $36.5 Million to Boost LYMPHIR Commercialization

Citius Oncology Secures $36.5 Million to Boost LYMPHIR Commercialization

Citius Oncology Secures $36.5 Million to Boost LYMPHIR Commercialization